CTOs on the Move

Rafael Pharmaceuticals

www.rafaelpharma.com

 
We are a pioneering, clinical-stage, metabolic oncology therapeutics company, focused on transforming the lives of patients with hard to treat cancers by applying our deep understanding of the unique bio-energetic processes specific to cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Cahaba Family Medicine

Cahaba Family Medicine Residency is an unopposed, community-based family medicine training program dually accredited by both the ACGME and AOA. Resurrection Family Medicine is now the Cahaba Urban Residency.

Navidea

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manoceptâ„¢ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea`s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea`s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company`s pipeline through global partnering and commercialization efforts.

CHEMINPHARMA

CHEMINPHARMA is a Farmington, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stat-Tech Services

Stat-Tech Services is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix`s proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.